\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burd	len									
hours per response:	0.5									

					-				
1. Name and Address of Reporting Ferson				2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ALLO]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Chang David D					X	Director	10% Owner		
	(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	X	Officer (give title below)	Other (specify below)		
				04/26/2019	President and CEO				
	(Street) SOUTH SAN			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Joint/Group Filing (Check Applicable		
FRANCISCO	CA	94080		X	Form filed by One Report	0			
						Form filed by More than (Person	One Reporting		
	(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)						5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	04/26/2019		J ⁽¹⁾		11,753	A	\$0.00	1,113,591	Ι	See footnote ⁽²⁾	
Common Stock								2,170,299 ⁽³⁾	D		
Common Stock								848,022	I	See footnote ⁽⁴⁾	
Common Stock								848,022	I	See footnote ⁽⁵⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of I		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

1. Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. 2. Securities held in the name of the Chang 2006 Family Trust.

3. Includes 1,674 shares of the Issuer's common stock acquired by the reporting person on March 15, 2019 pursuant to an employee stock purchase program.

4. Securities held in the name of the Julia Chang 2018 Irrevocable Trust, of which the reporting person is Trustee and his daughter is the beneficiary.

5. Securities held in the name of the Robert Chang 2018 Irrevocable Trust, of which the reporting person is Trustee and his son is the beneficiary.

Remarks:

/s/ Veer Bhavnagri, Attorney-

in-Fact

04/30/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.